398456-82-1

Basic information

• Product Name: 3-BROMO-2,6-DIFLUOROBENZALDEHYDE
• Synonyms: 3-BROMO-2,6-DIFLUOROBENZALDEHYDE;3-Bromo-2,6-difluorobenzaldehyde 98%;3-Bromo-2,6-difluorobenzaldehyde98%
• CAS NO: 398456-82-1
• Molecular Formula: C₇H₃BrF₂O
• Molecular Weight: 221
• Mol File: 398456-82-1.mol

Chemical Properties

• Melting Point: 53-57°C
• Boiling Point: 223℃
• Flash Point: 89℃
• Appearance: /
• Density: 1.758
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Sensitive: Air Sensitive
• CAS DataBase Reference: 3-BROMO-2,6-DIFLUOROBENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-2,6-DIFLUOROBENZALDEHYDE(398456-82-1)
• EPA Substance Registry System: 3-BROMO-2,6-DIFLUOROBENZALDEHYDE(398456-82-1)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 398456-82-1(Hazardous Substances Data)

Usage

Uses

3-Bromo-2,6-difluorobenzaldehyde is used as a pharmaceutical intermediate.

Upstream product

• 348-57-2 2,4-difluorobromobenzene 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 438050-05-6 (3-bromo-2,6-difluorophenyl)methanol 
• 1193348-29-6 5-(3-bromo-2,6-difluorophenyl)-4-chloro-1-(4-chlorophenyl)-1H-imidazole 

Relevant articles and documents

ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS

The present invention relates to a compound represented by formula I: and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

AMIDE COMPOUND

A compound having GPR52 agonist activity or a salt thereof is provided. The compound can be provided as a preventive/therapeutic agent for schizophrenia or the like. The compound is represented by the following formula: wherein A represents —CONRa— or —NRaCO—, Ra represents a hydrogen atom or the like,B represents a hydrogen atom or the like,a ring Cy1 represents a six-membered aromatic ring which may have one or more substituents in addition to a group represented by -A-B,a ring Cy2 represents a six-membered ring which may be substituted with a halogen atom or the like,a ring Cy3 represents a five- or six-membered ring which may have one or more substituents;X represents C1-2 alkylene or the like,m represents an integer of 0 to 2, anda ring Cy4 represents a six-membered aromatic ring which may have one or more substituents.

Pharmaceutical compounds

This invention relates to compounds of formula (I) where R1 to R12, —W—V—, —X—Y—, m and n have the values defined in claim 1, their preparation and use as pharmaceuticals.